Рекомендации ESPEN-ESPGHAN-ECFS по диетотерапии при муковисцидозе у младенцев, детей и взрослых

Trapnell ВС, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibres 2009;8:370-7

384

Colombo C, Fredella C, Russo MC, Faelli N, Motta V, Valmarana L, et al. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas 2009;38:693-9

385

Kashirskaya NY, Kapranov N1, Sander-Struckmeier S, Kovalev V Safety and efficacy of Creon(R) Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibres 2014;14:275-81

386

Munck A, Duhamel JF, Lamireau T, Le Luyer B, Le Tallec C, Bellon G, et al. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibres 2009;8:14-8

387

Graff GR, Maguiness K, McNamara J, Morton R, Boyd D, Beckmann K, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther 2010;32:89-103

388

Graff GR, McNamara J, Royall J, Caras S, Forssmann K. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study. Clin Drug Investig 2010;30:351-64